<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lower effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the boceprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="VO3AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the atazanavir, the darunavir or the lopinavir boosted with cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of tenofovir alafenamide due to decrease of its absorption by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
